Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.69 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.55 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | PRKCI | P41743 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | RXRG | P48443 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18563482 | 0.86 | FFAR1 (0.67) | FFAR1FFAR4AKR1B1KEAP1LIPG | |
| SCHEMBL29381971 | 0.84 | FFAR1 (0.69) | FFAR1FFAR4AKR1B1KEAP1LIPG | |
| SCHEMBL7347912 | 0.84 | FFAR1 (0.69) | FFAR1FFAR4AKR1B1KEAP1LIPG | |
| SCHEMBL1744794 | 0.84 | FFAR1 (0.85) | FFAR1FFAR4AKR1B1 | |
| SCHEMBL25146744 | 0.84 | FFAR1 (0.65) | FFAR1FFAR4AKR1B1KEAP1LIPG | |
| SCHEMBL9051375 | 0.83 | FFAR1 (0.64) | FFAR1FFAR4KEAP1 | |
| SCHEMBL23512360 | 0.83 | FFAR1 (0.62) | FFAR1FFAR4AKR1B1KEAP1LIPG | |
| SCHEMBL8618654 | 0.82 | FFAR1 (1.00) | FFAR1FFAR4AKR1B1KEAP1MMP12 | |
| SCHEMBL1211561 | 0.82 | FFAR1 (1.00) | FFAR1FFAR4AKR1B1KEAP1MMP12 | |
| SCHEMBL18165305 | 0.82 | FFAR1 (0.77) | FFAR1FFAR4AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2021-05-18 | — | — | US | disclosed |
| EP-3722277-A2 | 3'END CAPS FOR RNA-INTERFERRING AGENTS FOR USE IN RNA | Novartis AG (CH) | 2020-10-14 | — | — | EP | disclosed |
| US-10227588-B2 | 3′end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2019-03-12 | — | — | US | disclosed |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-10-20 | — | — | US | disclosed |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227588-B2 | 3′end caps for RNAi agents for use in RNA interference | RNGTT, NSUN2, NSUN3 | FFAR1 4650/4885FFAR4 4785/4885AKR1B1 4233/4885 |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | GPR119, INSR, GPR65 | FFAR1 6/4885FFAR4 12/4885AKR1B1 141/4885 |
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | RNGTT, NSUN2, NSUN3 | FFAR1 4650/4885FFAR4 4785/4885AKR1B1 4233/4885 |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | RNGTT, NSUN2, NSUN3 | FFAR1 4656/4885FFAR4 4787/4885AKR1B1 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.